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Lactulose drives a reversible 
reduction and qualitative 
modulation of the faecal microbiota 
diversity in healthy dogs
Marisa da fonseca ferreira  , Silke Salavati Schmitz, Jeffrey Joseph Schoenebeck  , 
Dylan neil clements, Susan Mary Campbell, Donna elaine Gaylor, Richard J. Mellanby, 
Adam George Gow & Mazdak Salavati  
Hepatic encephalopathy is a frequent and debilitating complication of liver disorders. Lactulose is an 
established and reasonably effective treatment, yet with incompletely understood mechanisms of 
action. The aims of this study were to examine how the faecal microbiota composition changed before, 
during and after lactulose treatment in a large animal model. Healthy, privately owned dogs (n = 18) 
completed a prospective cohort study. Faecal samples were collected weekly, while the subjects were 
either on their usual diet (week 1), or a standardised diet (weeks 2–9), with added oral lactulose in weeks 
6–7. DNA extraction and 16S rRNA gene sequencing were undertaken. Faecal samples from week 
7 had a significantly lower microbiota richness/diversity, based on observed operational taxonomic 
units, Shannon/Chao1 indexes and Pielou’s Evenness. Beta diversity based on UniFrac distances 
was significantly different in week 7 compared to weeks 1, 5 and 9. At the phylum level, week 7 was 
associated with a significant increase of Firmicutes and Actinobacteria, and a decrease of Bacteroidetes 
and Fusobacteria, when compared to weeks 5 and 9. In summary, we have shown that lactulose induces 
a reversible qualitative and quantitative change of the faecal microbiota, which may explain its clinical 
efficacy in the management of hepatic encephalopathy.
Hepatic encephalopathy (HE) is a frequent and debilitating neurological complication in patients with liver dis-
ease. Severe (grades 3–4) HE is associated with higher in-hospital and 30-day mortality, independently of extra-
hepatic organ failures1, and higher liver transplantation 90-day wait list mortality2. Covert (minimal and grade 1) 
HE directly results in human morbidity, being an independent predictor of reduced health-related quality of life 
and poor sleep quality3. Furthermore, HE contributes to a substantial economic burden. In the USA alone, total 
HE-related hospitalisation charges amounted to $7.245 billion in 20094, and up to $58,625 per patient in 20125.
The pathogenesis of HE is not fully understood6. Several neurotoxins and precipitating factors have been 
implicated, with ammonia being the most well characterised one. In advanced liver disease, this gut-derived neu-
rotoxin may accumulate in the blood and in the brain, due to lack of hepatic conversion into urea and subsequent 
urinary excretion7. Clinically, in human cirrhosis, plasma ammonia has been correlated with both the severity of 
HE and the frequency of other organ failures, and was identified as an independent predictor of 28-day mortality8.
Lactulose, a synthetic non-absorbable disaccharide, is a commonly used medication, with or without the addi-
tion of the antibiotic rifaximin, for both the treatment and prevention of HE, with a reasonable evidence of effi-
cacy and added benefits in reducing morbidity and mortality9,10. The postulated benefits of lactulose include: (1) 
decreased colonic transit time and pH, leading to decreased ammonia production and absorption; (2) increased 
bacterial assimilation of ammonia; (3) decreased bacterial generation of ammonia; (4) production shift from toxic 
to non-toxic short-chain fatty acids (SCFA); and (5) reduced bacterial DNA translocation11,12. Yet, its mechanisms 
of action remain incompletely elucidated.
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Faecal dysbiosis is known to occur in covert and overt HE. Cirrhotic patients with minimal HE (MHE) har-
bour a higher proportion of urease-producing Streptococcus salivarius in stool samples, positively correlating with 
serum ammonia accumulation13. Additionally, the cirrhosis dysbiosis ratio (CDR), a previously validated ratio 
of autochthonous to non-autochthonous taxa in stool samples of cirrhotic patients, is lowered after development 
of severe HE, indicating worsened dysbiosis, and associated with 30-day mortality and organ failure14. Moreover, 
the presence of specific bacterial families (Alcaligenaceae, Porphyromonadaceae, Enterobacteriaceae) is strongly 
associated with poor cognition and inflammation in HE patients15. Considering the ongoing evidence regarding 
microbiome disruption in cirrhosis and HE16, it is likely that manipulation of the microbiota may contribute to 
improved outcomes. Interventions with proposed positive impact have so far included probiotics17, diet18 and 
faecal microbiota transplantation19.
The impact of lactulose in ameliorating cirrhosis and HE-associated faecal dysbiosis is controversial. A 
direct impact has been supported by studies based on culture-dependent methodologies, namely: increased 
Bifidobacterium, Lactobacillus and Bacteroidaceae colonies, and reduced Enterobacteriaceae, Enterococcus 
and yeasts in patients with MHE, alongside with improved blood ammonia, psychometric tests and reduced 
risk of developing overt HE20; and increased total aerobic and anaerobic bacterial counts, and lactobacilli in 
cirrhotic patients without clinical HE, alongside with decreased faecal pH21. Conversely, studies based on 
culture-independent techniques have not substantiated an effect of lactulose in the microbiome of cirrhotic 
patients without HE22 and have reported only a minimal change in cirrhotic patients with HE14, including after 
lactulose withdrawal23.
However, no study using next generation sequencing techniques has assessed quantitative and qualita-
tive changes of the intestinal or faecal microbiome, i.e. changes based on both the abundance and the pres-
ence or absence of microbial communities, after lactulose treatment in patients entirely naïve to lactulose. The 
effects of oral lactulose on the faecal microbiome of healthy humans have only been evaluated through either 
culture-based24–26 or culture-independent methods targeting predominant bacterial groups27–30. As diet was only 
standardised in two of those studies24,30, it seems likely that a variable diet could have impacted results31.
The human faecal microbiome is closer to the canine faecal microbiome when compared to pigs or mice32. 
Dogs evolved to cohabit with people, and hence adapted to a similar diet33. As they are frequently kept as com-
panion animals, they are also exposed to the same environment. In addition, dogs can equally suffer from HE 
and lactulose is frequently used as supportive treatment in this condition34. Consequently, companion dogs can 
represent a useful comparative model to explore the faecal microbiome in HE as well as the effects of certain 
interventions on its composition, richness and function.
Therefore, the aims of this study were to investigate the magnitude and duration of quantitative and qualitative 
changes of the faecal microbiota by lactulose in healthy privately-owned dogs fed a standardised commercial 
diet. It was hypothesised that oral lactulose administration would significantly and transiently change the faecal 
microbiota in healthy dogs.
Methods
Prospective cohort study design. Dogs owned by members of staff at the Hospital for Small Animals, the 
Royal (Dick) School of Veterinary Studies, University of Edinburgh, were recruited with the following inclusion 
criteria: no current history of any disease; up to date vaccination and deworming records; and no current or 
recent administration of medications. A faecal sample was requested to be collected from each subject weekly, 
pertaining to the interventions schematised in Fig. 1.
The standardised diet was a commercial maintenance diet for adult dogs (Hill’s™ Science Plan™ Canine Adult 
Advanced Fitness™ Large Breed with Chicken, Hill’s Pet Nutrition Ltd., Guildford, UK) and the lactulose was a 
3.5 g/5 ml oral solution (Sandoz Ltd, Hampshire, UK). The dose of lactulose was calculated at 0.5 ml/kg and given 
every 12 hours, unless excessively soft or unformed faeces were noticed, at which point the subjects’ owners would 
notify one of the authors (MFF) and subsequently decrease the dose by 25% each time, aiming to achieve a soft 
faecal consistency that would be still amenable for manual collection.
Faecal samples were collected into plain bijoux tubes, kept frozen at −20 °C for a maximum of 24 hours and 
transferred afterwards to a −80 °C archiving freezer.
Informed consent was obtained from each subject’s owner. The study was approved by the University of 
Edinburgh’s Veterinary Ethical Review Committee (reference number 112–14) and carried out in accordance 
with the institution’s relevant guidelines and regulations.
Faecal DNA extraction, amplification and sequencing. Each sample was defrosted, manually 
homogenised and DNA extraction performed with a commercial kit (PowerSoil® DNA Isolation Kit, MO 
BIO Laboratories, Inc., Carlsbad, CA, USA) according to the manufacturer’s instructions35. Amplification of 
DNA was undertaken with PCR of the hypervariable V4 region of the 16S ribosomal RNA (rRNA) gene, using 
dual-indexing primers (515F/806R), followed by amplicon quantification (Quant-iT™ PicoGreen®, Invitrogen, 
Figure 1. Longitudinal interventions in cohort of healthy owned dogs, designed to assess the faecal microbiota.
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Ltd., Paisley, UK) and pooling, as previously described36,37. Standard 16S rRNA library preparation and sequenc-
ing with the Illumina® MiSeq® (v2 150PE) platform were performed by Edinburgh Genomics (The University of 
Edinburgh, UK).
Data analysis. Software packages for data analysis included the Quantitative Insights Into Microbial Ecology 
(QIIME2™, https://qiime2.org/) pipeline, RStudio® (version 1.1.453, © 2009–2018 RStudio, Inc., Boston, MA, 
US) with the package qiime2R (v0.12), as well as GraphPad Prism® (version 7, GraphPad Software Inc., La Jolla, 
CA, US).
The paired-end raw reads (Supplementary Data Mendeley Data) were analysed using QIIME2™. 
Briefly, sequence data with sequence quality information was imported through the “fastq manifest” format 
PairedEndFastqManifestPhred33. Demultiplexed sequence counts were summarised showing a median of 58,478 
sequences per sample, with a minimum of 27,297 and maximum of 134,220. Sequence quality trimming, chimera 
filtering and feature table construction was performed through the DADA2 pipeline38. Mapping of feature iden-
tifiers to sequences was created using links for the Basic Local Alignment Search Tool (BLAST)39, and multiple 
sequence alignment of the sequences was undertaken by the Fast Fourier Transform (MAFFT) program40. This 
was followed by filtering of the alignment with the mask plugin41, generation of a phylogenetic tree with the 
FastTree program42 and application of midpoint rooting. The QIIME2™ q2-diversity plugin was used for rarefac-
tion analysis and computation of alpha diversity metrics (observed operational taxonomic units [OTUs], Shannon 
diversity index, Chao1 and Pielou’s Evenness), as well as beta diversity metrics (weighted and unweighted UniFrac 
distances). Finally, assigning taxonomy to sequences was performed with a pre-trained Naïve Bayes classifier 
(Greengenes 13_8 99% OTUs) through the QIIME2™ q2-feature-classifier plugin43.
A human-extrapolated CDR: ratio of commensal autochthonous taxa (Lachnospiraceae, Ruminococcaceae, 
Veillonellaceae, and Clostridiales Insertae Sedis XIV) to potentially pathogenic non-autochthonous taxa 
(Enterobacteriaceae and Bacteroidaceae)44, was calculated without the inclusion of Clostridiales Insertae Sedis 
XIV, as this taxon was not detected in the studied population.
Statistical analyses used included descriptive statistics, as well as the following inferential statistical tests: 
Kruskal-Wallis test to compare differences between subjects regarding alpha diversity metrics; Wilcoxon 
matched-pairs signed rank test to compare differences between weeks regarding alpha diversity metrics, tax-
onomy frequencies and the CDR; paired t-test to compare differences between weeks regarding the presence 
of Lachnospiraceae; and Permutational Multivariate Analysis of Variance (PERMANOVA) test to compare 
differences between subjects and weeks regarding beta diversity metrics45. Normality was assessed with the 
Shapiro-Wilk test. Statistical significance level was set at p < 0.05.
Results
Population’s baseline characteristics. A total of 21 dogs were enrolled, with a median age of 5 years 
(range of 2–10 years). Sex distribution included 12 females (11 neutered) and 9 males (7 neutered). Just over half 
(n = 11) of the cohort was represented by crossbred dogs, with the remaining 10 dogs distributed as follows: two 
each of English Cocker Spaniel, English Springer Spaniel, Border Collie and Podenco; and one each of Boston 
Terrier and Labrador Retriever.
Adherence to study protocol and side effects related to lactulose administration. Three dogs 
did not complete the study for the following reasons: acute diarrhoea following dietary indiscretion (n = 1); 
requirement of a NSAID (meloxicam) for pain management secondary to presumptive degenerative joint disease 
(n = 1); and lip fold dermatitis after being licked by another dog in the household once starting lactulose (n = 1). 
In addition, two faecal samples (one each from weeks 4 and 8) were accidentally not collected. In total, 172 faecal 
samples were analysed, one of which failed sequencing (week 6). Side effects associated with lactulose adminis-
tration included excessively soft faeces (n = 7) and unformed faeces (n = 1), all resolving after a dose reduction of 
25% and 50%, respectively, therefore not requiring a drop out from the study.
Alpha diversity. Community richness and diversity values were different between subjects regarding the fol-
lowing metrics: observed OTUs (p < 0.0001), Shannon diversity index (p = 0.0025), Chao1 index (p < 0.0001) and 
Pielou’s Evenness (p < 0.0001). Assessment of community richness and diversity across time is shown in Fig. 2. 
There was a reduction of all the above metrics at week 7 (standardised diet and oral lactulose), when compared 
to weeks 1 (usual diet), 5 (standardised diet) and 9 (standardised diet after having stopped lactulose). Conversely, 
values from weeks 1, 5 and 9 didn’t differ from each other apart from Shannon diversity index values between 
week 5 and 9 (Table 1).
Beta diversity. Bacterial community presence/absence (qualitative) and abundance (quantitative) assess-
ments with unweighted and weighted UniFrac distances, respectively, are illustrated in Fig. 3. These were overall 
different between subjects (p < 0.001). When analysed across time, the distances at week 7 were different from 
weeks 1, 5 and 9. However, values at weeks 1, 5 and 9 didn’t differ from each other (Table 2).
taxonomy. The relative and absolute distribution of phyla abundance across time is depicted in Fig. 4. 
Irrespective of week number (5, 7 or 9), the most abundant phylum was Firmicutes, followed by Bacteroidetes. 
A shift of phyla was observed at week 7, with the third most abundant phylum being Actinobacteria, followed by 
Fusobacteria and Proteobacteria. In contrast, for both weeks 5 and 9, Fusobacteria was the third most abundant 
phylum, followed by Proteobacteria and Actinobacteria. Moreover, when compared to weeks 5 and 9, week 7 was 
associated with a higher abundance of both Firmicutes (p = 0.0056 and 0.0047, respectively) and Actinobacteria 
(p = 0.0090 and 0.0104, respectively), and lower abundance of both Bacteroidetes (p = 0.0304 and 0.0120, respec-
tively) and Fusobacteria (p = 0.0040 and 0.0008, respectively). The abundance of these phyla was similar between 
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weeks 5 and 9 (Firmicutes, p = 0.6397; Actinobacteria, p = 0.6095; Bacteroidetes, p = 0.8650; and Fusobacteria, 
p = 0.1964).
A total of 20 families were found to be present in the microbiota of at least half of the subjects at one or 
more time points (Fig. 5a). Different abundances across time were found in eight families (Fig. 5b), six of which 
showed a different abundance in week 7 when compared to weeks 5 and 9 (Fig. 5c), while both these time points 
Figure 2. Variation of the canine faecal microbiota, assessed by alpha diversity metrics. (a) Shannon diversity 
index across a cohort of healthy owned dogs (letters a-u) while either on their usual diet (Original, week 1), 
a standard diet (Standard_Pre, weeks 2–5), a standard diet and oral lactulose (Lactulose, weeks 6–7), or a 
standard diet after having stopped lactulose (Standard_Post, weeks 8–9). (b–e) Box and whiskers plots (median, 
25th and 75th quartiles), depicting different alpha diversity metrics at selected weeks: observed operating 
taxonomic units (OTUs) (b); Shannon diversity index (c); Chao1 index (d); and Pielou’s Evenness. (e) *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001 (Wilcoxon matched-pairs signed rank test).
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had similar abundances. Significant changes at week 7 included an increased representation of Veillonellaceae 
and Bifidobacteriaceae, and a decreased abundance of Fusobacteriaceae, Bacteroidaceae, Ruminococcaceae, 
Alcaligenaceae, Lachnospiraceae and Peptococcaceae.
cirrhosis dysbiosis ratio. When analysing the CDR across time (Fig. 6), the highest values were obtained at 
week 7 with a median of 25.07 (range of 0.08–460.04). These were different from week 1 (median 3.19, range 0.18–
30.98, p = 0.0079), week 5 (median 2.54, range 0.18–29.78, p = 0.0003) and week 9 (median 2.10, range 0.24–
15.75, p < 0.0001). Conversely, the CDRs calculated for weeks 1, 5 and 9 were similar to each other (p = 0.5678 for 
week 1 vs 5; p = 0.2288 for week 1 vs 9; and p = 0.5509 for week 5 vs 9).
Discussion
To date, there are no publications employing untargeted or global culture-independent methodologies to assess 
the faecal microbiome in healthy people receiving lactulose. In people with HE, further limitations often apply, 
given the common use of standard of care treatment by the time of study enrolment (lactulose, rifaximin, antac-
ids), precluding an evaluation of the microbiome in non-treated HE14,18.
Metric
Weeks 1 
vs 5
Weeks 1 
vs 7
Weeks 1 
vs 9
Weeks 5 
vs 7
Weeks 5 
vs 9
Weeks 7 
vs 9
Observed OTUsa 0.8056 <0.0001 0.7904 0.0002 0.3516 0.0003
Shannon diversity index 0.9843 0.0003 0.0814 <0.0001 0.0268 <0.0001
Chao1 index 0.7453 <0.0001 0.7379 0.0002 0.2690 0.0003
Pielou’s Evenness 0.7680 0.004 0.0898 0.0010 0.0898 0.009
Table 1. Statistical significances (p) of alpha diversity metrics for the canine faecal microbiota when compared 
across time. Cohort of healthy owned dogs while either on their usual diet (week 1), a standard diet (week 5), a 
standard diet and oral lactulose (week 7), or a standard diet after having stopped lactulose (week 9). Statistical 
test used: Wilcoxon matched-pairs signed rank test. aOperational Taxonomic Units.
Figure 3. Variation of the canine faecal microbiota, assessed by beta diversity metrics. (a,b) Principal 
coordinate analysis based on unweighted (a) and weighted (b) UniFrac distances. Cohort of healthy owned 
dogs while either on their usual diet (week 1), a standard diet (week 5), a standard diet and oral lactulose (week 
7), or a standard diet after having stopped lactulose (week 9). Samples from week 7 were significantly different 
(p < 0.01, PERMANOVA test) from weeks 1, 5 and 9, while none of the latter differed from each other.
Metric
Weeks 1 
vs 5
Weeks 1 
vs 7
Weeks 1 
vs 9
Weeks 5 
vs 7
Weeks 5 
vs 9
Weeks 7 
vs 9
Unweighted UniFrac 0.534 0.001 0.136 0.001 0.272 0.012
Weighted UniFrac 0.474 0.001 0.978 0.002 0.645 0.001
Table 2. Statistical significances (p) of beta diversity metrics for the canine faecal microbiota when compared 
across time. Cohort of healthy owned dogs while either on their usual diet (week 1), a standard diet (week 5), a 
standard diet and oral lactulose (week 7), or a standard diet after having stopped lactulose (week 9). Statistical 
test used: PERMANOVA.
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To the authors’ knowledge, this study is the first to investigate the effect of lactulose on the canine microbiota. 
Collectively, lactulose induced a reversible reduction and qualitative modulation of the faecal microbiota diversity 
in this population of healthy dogs, while on a commercial standardised diet. Both alpha and beta diversity metrics 
were affected and specific taxa were implicated in this change.
The impact of lactulose has been studied in healthy mice and pigs through culture-independent methods, 
most showing an increased alpha diversity, which is in contrast to the present study46–49. However, experimen-
tal animals are kept in laboratory-controlled conditions and both species are known to have a more distant 
Figure 4. Abundance of phyla in the canine faecal microbiota. Cohort of healthy owned dogs while either on 
a standard diet (week 5), a standard diet and oral lactulose (week 7), or a standard diet after having stopped 
lactulose (week 9). (a) Median relative abundance of different phyla. (b–f) Dot plots (including bars for median, 
25th and 75th quartiles) depicting absolute abundance of: Actinobacteria (b); Bacteroidetes (c); Firmicutes (d); 
Fusobacteria (e); and Proteobacteria (f). *p < 0.05; **p < 0.01; ***p < 0.001 (Wilcoxon matched-pairs signed 
rank test).
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microbiome from humans relative to dogs32. Assessing companion dogs, alongside maintaining the advantage of 
dietary control, may be therefore valuable given their natural shared environment with humans31.
No significant changes of the microbiota were observed in this study due to diet change alone. This is likely 
explained by the relative similarity of composition of commercial diets (most of the original diets consisted of 
Figure 5. Abundance of families in the canine faecal microbiota. Cohort of healthy owned dogs while either 
on a standard diet (week 5), a standard diet and oral lactulose (week 7), or a standard diet after having stopped 
lactulose (week 9). (a) Median relative abundance of families with counts present in at least 50% of dogs in 
at least one week group. (b) Dot plots (including bars for median, 25th and 75th quartiles) depicting absolute 
abundance of statistically significant families (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; Wilcoxon 
matched-pairs signed rank test). (c) Median relative abundance of statistically significant families (Wilcoxon 
matched-pairs signed rank test).
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various brands of dry dog food), in comparison to homemade or raw food50,51. There were marked inter-individual 
differences concerning overall alpha and beta diversity, which was not surprising, given the non-relatedness of the 
subjects and the diversity of breeds evaluated52,53.
Significant changes in the abundance of main phyla were observed with the introduction of lactulose 
and matched by changes noted at family taxa. Within the Firmicutes and Actinobacteria, Veillonellaceae and 
Bifidobacteriaceae increased; and decreases in Bacteroidaceae and Fusobacteriaceae likely reflect lower abun-
dances of Bacteroidetes and Fusobacteria.
Veillonellaceae was the most abundant family after the administration of lactulose. Its significance in liver 
disease has been controversial, as previous studies have reported both increases and decreases in human cirrhosis 
with and without HE13,14. Bacteria of this family convert lactate to acetate and butyrate54. Previously, the latter 
has been positively correlated with the presence of Veillonellaceae in canine faeces55. Increases in microorganisms 
producing these SCFA could be beneficial, as in people, acetate was negatively correlated with pro-inflammatory 
cytokines in cirrhosis, and butyrate was protective against the development of HE16. The administration of lactu-
lose has been associated with increased acetate and butyrate production, together with decreased branch-chained 
fatty acids isobutyrate and isovalerate46,47,56. Similarly to the present study, several others have reported increased 
numbers of faecal Bifidobacteriaceae24–30, which produce lactate and acetate57, as well as contribute to metabolic 
cross-feeding, stimulating other butyrate-producing bacteria58.
Reductions of both Fusobacteriaceae and Alcaligenaceae induced by oral lactulose have not been previously 
reported. This finding is potentially significant, as their presence in the stools of patients with cirrhosis and HE 
has been associated with worsened inflammation/endotoxaemia and poor performance on cognitive tests15. On 
the contrary, decreases in Bacteroidaceae24,26 and Ruminococcaceae30 have been previously reported with lac-
tulose administration. Bacteroides spp., are known to produce isovalerate59, as well as pro-inflammatory and 
barrier-disruptive neurotoxins/enterotoxins60, and β-glucuronidase61, a potential carcinogenic. Reduced faecal 
activity levels of this enzyme have been demonstrated previously with lactulose administration26,62. Besides pro-
ducing butyrate63, Ruminococcaceae and Lachnospiraceae are also known to produce β-glucuronidase64. The lack 
of a significant increase in Lactobacillaceae with lactulose administration has been demonstrated before; hence, 
this study confirms that it is not a major hallmark of lactulose use24,25,29,30.
CDR is a measure of dysbiosis in humans: healthy people are reported to have a higher ratio than patients with 
cirrhosis, and the presence of HE was associated with an even lower CDR14. Although extrapolated from studies 
in people, the increase of CDR during lactulose administration could represent improvement of dysbiosis, despite 
an overall lower microbiota diversity and richness.
Limitations of this study include the small number of dogs, the collection of voided faecal samples rather than 
mucosal or luminal colonic samples, the lack of storage buffer/cryoprotectant and the fact that 16S rRNA gene 
sequencing allows assessment of taxonomy and abundance, but no species level resolution, nor extrapolation of 
functional data from the microbiome. However, given the longitudinal study design, each subject could serve 
as their own control, allowing observation of general trends of microbiota changes. For ethical reasons, inva-
sive collection methods were not employed in these privately owned animals47,65. Short-term storage of faecal 
samples without cryopreservative or buffer is likely to not impact on major phyla distribution66,67. To investigate 
functional changes of the microbiome, high-throughput techniques (whole metagenome shotgun sequencing), 
metabolomics or metatranscriptomics could have been performed, but this was not within the scope of the cur-
rent study.
In conclusion, lactulose can drive a reversible quantitative and qualitative modulation of the faecal micro-
biota in this dog model. Future research is warranted to focus on the investigation of microbiome dynamics 
in canine models of spontaneous naturally occurring HE (e.g. congenital portosystemic shunts)68. This could 
Figure 6. Cirrhosis dysbiosis ratio (CDR), calculated from the canine faecal microbiota, extrapolated from 
humans. Cohort of healthy owned dogs while either on their usual diet (week 1), a standard diet (week 5), a 
standard diet and oral lactulose (week 7), or a standard diet after having stopped lactulose (week 9). **p < 0.01; 
***p < 0.001; ****p < 0.0001 (Wilcoxon matched-pairs signed rank test).
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include similar longitudinal studies to assess effects before and after lactulose treatment or the correlation or 
comparison with other management strategies. Allowing for more targeted treatment endpoints could not only 
advance knowledge but also improve outcomes in HE.
Data Availability
The datasets generated and/or analysed during the current study are available in the Mendeley Data repository, 
https://doi.org/10.17632/8ctyv86ccp.1.
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